Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 16.12
KMDA's Cash-to-Debt is ranked lower than
54% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. KMDA: 16.12 )
Ranked among companies with meaningful Cash-to-Debt only.
KMDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.65  Med: 3.28 Max: N/A
Current: 16.12
Equity-to-Asset 0.67
KMDA's Equity-to-Asset is ranked higher than
55% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. KMDA: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
KMDA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.48 Max: 0.71
Current: 0.67
0.27
0.71
Piotroski F-Score: 5
Altman Z-Score: 4.37
Beneish M-Score: -1.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -7.07
KMDA's Operating Margin % is ranked higher than
62% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. KMDA: -7.07 )
Ranked among companies with meaningful Operating Margin % only.
KMDA' s Operating Margin % Range Over the Past 10 Years
Min: -121.42  Med: -16.25 Max: 5.83
Current: -7.07
-121.42
5.83
Net Margin % -8.69
KMDA's Net Margin % is ranked higher than
62% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. KMDA: -8.69 )
Ranked among companies with meaningful Net Margin % only.
KMDA' s Net Margin % Range Over the Past 10 Years
Min: -170.4  Med: -17.36 Max: 0.63
Current: -8.69
-170.4
0.63
ROE % -9.67
KMDA's ROE % is ranked higher than
61% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. KMDA: -9.67 )
Ranked among companies with meaningful ROE % only.
KMDA' s ROE % Range Over the Past 10 Years
Min: -196.88  Med: -15.11 Max: 1.02
Current: -9.67
-196.88
1.02
ROA % -6.71
KMDA's ROA % is ranked higher than
65% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. KMDA: -6.71 )
Ranked among companies with meaningful ROA % only.
KMDA' s ROA % Range Over the Past 10 Years
Min: -59.18  Med: -10.19 Max: 0.39
Current: -6.71
-59.18
0.39
ROC (Joel Greenblatt) % -10.40
KMDA's ROC (Joel Greenblatt) % is ranked higher than
68% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. KMDA: -10.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KMDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -179.58  Med: -21.93 Max: 15.92
Current: -10.4
-179.58
15.92
3-Year Revenue Growth Rate 0.20
KMDA's 3-Year Revenue Growth Rate is ranked lower than
55% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. KMDA: 0.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KMDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.8  Med: 4.6 Max: 50.5
Current: 0.2
-8.8
50.5
GuruFocus has detected 4 Warning Signs with Kamada Ltd $KMDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

KMDA Guru Trades in Q1 2016

Jim Simons 170,300 sh (+2.41%)
John Paulson 736,117 sh (-0.44%)
» More
Q2 2016

KMDA Guru Trades in Q2 2016

Jim Simons 172,800 sh (+1.47%)
John Paulson 736,117 sh (unchged)
» More
Q3 2016

KMDA Guru Trades in Q3 2016

Jim Simons 188,500 sh (+9.09%)
John Paulson 730,800 sh (-0.72%)
» More
Q4 2016

KMDA Guru Trades in Q4 2016

Jim Simons 227,000 sh (+20.42%)
John Paulson 730,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SRNE, OTCPK:CLVLF, OTCPK:MXDHF, OTCPK:RCAR, NAS:IDRA, NAS:MNKD, OTCPK:ELVAF, NAS:SGMO, NAS:IMGN, NAS:AVXL, OTCPK:THERF, NAS:CCXI, NAS:CGEN, NAS:MNOV, NAS:ABEO, NAS:CYAD, OTCPK:SPHRY, OTCPK:SPRWF, NAS:TGTX, NAS:SVA » details
Traded in other countries:K3M.Germany, KMDA.Israel,
Kamada Ltd is an orphan drug, plasma-derived protein Therapeutics Company and develops & produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Ratios

vs
industry
vs
history
PB Ratio 3.77
KMDA's PB Ratio is ranked higher than
50% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. KMDA: 3.77 )
Ranked among companies with meaningful PB Ratio only.
KMDA' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 2.94 Max: 12.47
Current: 3.77
1.54
12.47
PS Ratio 3.31
KMDA's PS Ratio is ranked higher than
71% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. KMDA: 3.31 )
Ranked among companies with meaningful PS Ratio only.
KMDA' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.95 Max: 15.93
Current: 3.31
1.61
15.93
Price-to-Operating-Cash-Flow 128.95
KMDA's Price-to-Operating-Cash-Flow is ranked lower than
92% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. KMDA: 128.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
KMDA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 102.78  Med: 115.05 Max: 134.49
Current: 128.95
102.78
134.49
Current Ratio 2.83
KMDA's Current Ratio is ranked lower than
59% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. KMDA: 2.83 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.39  Med: 3.14 Max: 4.92
Current: 2.83
2.39
4.92
Quick Ratio 1.89
KMDA's Quick Ratio is ranked lower than
66% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. KMDA: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.32 Max: 4.02
Current: 1.89
1.69
4.02
Days Inventory 183.07
KMDA's Days Inventory is ranked lower than
68% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. KMDA: 183.07 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 97.6  Med: 154.27 Max: 183.07
Current: 183.07
97.6
183.07
Days Sales Outstanding 107.63
KMDA's Days Sales Outstanding is ranked lower than
75% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. KMDA: 107.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.76  Med: 97.76 Max: 135.5
Current: 107.63
45.76
135.5
Days Payable 143.08
KMDA's Days Payable is ranked higher than
79% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. KMDA: 143.08 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 116.34 Max: 174.99
Current: 143.08
89.24
174.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
KMDA's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. KMDA: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KMDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.2  Med: -9.3 Max: -0.4
Current: -0.4
-33.2
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 5.69
KMDA's Price-to-Net-Current-Asset-Value is ranked higher than
58% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. KMDA: 5.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KMDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.41  Med: 8.74 Max: 33.64
Current: 5.69
2.41
33.64
Price-to-Tangible-Book 3.78
KMDA's Price-to-Tangible-Book is ranked higher than
58% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. KMDA: 3.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KMDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.35  Med: 4.02 Max: 9.16
Current: 3.78
1.35
9.16
Price-to-Median-PS-Value 1.12
KMDA's Price-to-Median-PS-Value is ranked lower than
60% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. KMDA: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KMDA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 0.93 Max: 2.21
Current: 1.12
0.65
2.21
Earnings Yield (Greenblatt) % -2.16
KMDA's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. KMDA: -2.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KMDA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.18  Med: 0.9 Max: 1.9
Current: -2.16
-2.18
1.9

More Statistics

Revenue (TTM) (Mil) $77.49
EPS (TTM) $ -0.18
Beta1.13
Short Percentage of Float0.05%
52-Week Range $3.26 - 7.25
Shares Outstanding (Mil)36.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 102 135 194
EPS ($) -0.12 0.26 0.69
EPS without NRI ($) -0.12 0.26 0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study... Feb 21 2017
Kamada Ltd. :KMDA-US: Earnings Analysis: 2016 By the Numbers : February 9, 2017 Feb 09 2017
Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of... Feb 08 2017
Kamada reports 4Q loss Feb 06 2017
Kamada reports 4Q loss Feb 06 2017
Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 Feb 06 2017
Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6 Feb 01 2017
Kamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on... Jan 23 2017
ETFs with exposure to Kamada Ltd. : January 20, 2017 Jan 20 2017
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272 Jan 09 2017
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III Jan 05 2017
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S. Jan 05 2017
Allergan Natrelle Inspira Breast Implants Approved in the U.S. Jan 04 2017
ETFs with exposure to Kamada Ltd. : December 14, 2016 Dec 14 2016
ETFs with exposure to Kamada Ltd. : December 2, 2016 Dec 02 2016
Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings? Nov 14 2016
Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016 Nov 10 2016
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies... Nov 07 2016
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies... Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)